Quarterly ResultMay 12, 2026, 07:17 AM
Olema Pharma Q1 Net Loss Widens to $53.1M; R&D Expenses Up
AI Summary
Olema Pharmaceuticals reported a widened net loss of $53.1 million for the first quarter of 2026, compared to $30.4 million in the same period last year, primarily due to increased research and development expenses. The company's total operating expenses rose to $58.0 million. Despite the loss, Olema maintained a strong liquidity position with $505.3 million in cash, cash equivalents, and marketable securities, and raised $41.9 million through an at-the-market offering.
Key Highlights
- Net loss for Q1 2026 widened to $53.1 million, compared to $30.4 million in Q1 2025.
- Research and development expenses increased to $49.2 million in Q1 2026 from $30.6 million in Q1 2025.
- General and administrative expenses rose to $8.8 million in Q1 2026 from $4.2 million in Q1 2025.
- Total operating expenses were $58.0 million in Q1 2026, up from $34.9 million in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled $505.3 million as of March 31, 2026.
- Net cash used in operating activities was $46.0 million in Q1 2026, compared to $44.0 million in Q1 2025.
- Net cash provided by financing activities was $45.7 million in Q1 2026, up from $0.2 million in Q1 2025.
- Issued 1,712,739 common shares via ATM offering for $41.9 million net proceeds in Q1 2026.
Price Impact
More from OLMA